Fungal microbiota dysbiosis in IBD PMID: 26843508 RUN2
Download from source ↗Dataset overview
Fungal microbiota dysbiosis in IBD.
Abstract
<h4>Objective</h4>The bacterial intestinal microbiota plays major roles in human physiology and IBDs. Although some data suggest a role of the fungal microbiota in IBD pathogenesis, the available data are scarce. The aim of our study was to characterise the faecal fungal microbiota in patients with IBD.<h4>Design</h4>Bacterial and fungal composition of the faecal microbiota of 235 patients with IBD and 38 healthy subjects (HS) was determined using 16S and ITS2 sequencing, respectively. The obtained sequences were analysed using the Qiime pipeline to assess composition and diversity. Bacterial and fungal taxa associated with clinical parameters were identified using multivariate association with linear models. Correlation between bacterial and fungal microbiota was investigated using Spearman's test and distance correlation.<h4>Results</h4>We observed that fungal microbiota is skewed in IBD, with an increased Basidiomycota/Ascomycota ratio, a decreased proportion of <i>Saccharomyces cerevisiae</i> and an increased proportion of <i>Candida albicans</i> compared with HS. We also identified disease-specific alterations in diversity, indicating that a Crohn's disease-specific gut environment may favour fungi at the expense of bacteria. The concomitant analysis of bacterial and fungal microbiota showed a dense and homogenous correlation network in HS but a dramatically unbalanced network in IBD, suggesting the existence of disease-specific inter-kingdom alterations.<h4>Conclusions</h4>Besides bacterial dysbiosis, our study identifies a distinct fungal microbiota dysbiosis in IBD characterised by alterations in biodiversity and composition. Moreover, we unravel here disease-specific inter-kingdom network alterations in IBD, suggesting that, beyond bacteria, fungi might also play a role in IBD pathogenesis.
doi:10.1136/gutjnl-2015-310746 ↗ PMID 26843508 ↗ PMC5532459 ↗
Study facts
- Organism
- —
- Platform
- —
- Age group
- —
- Disease groups
- Non-IBD controls
- Anatomical sites
- —
Data availability
Specific data assets have not been resolved from the source yet — see the source repository below for the full file listing.
Strengths & limitations for reuse
Strengths
- Participant counts are documented
- Sample counts are documented
Limitations
- Not documented: raw reads are advertised
- Not documented: feature/otu tables are advertised
- Not documented: taxonomic tables are advertised
Extraction evidence & provenance
Each extracted field is shown with the source excerpt and location used to resolve it.
Assay
| Field | Value | Evidence |
|---|---|---|
assay.sequencing_type |
amplicon_its inferred |
Using ITS2 sequencing, we then assessed the composition of the fungal microbiota Section |
assay.target_region |
ITS2 |
Using ITS2 sequencing, we then assessed the composition of the fungal microbiota Section |
Cohort
| Field | Value | Evidence |
|---|---|---|
cohort.disease_activity_metadata_available |
True |
in flare compared with remission Section |
cohort.non_ibd_controls |
38 |
235 patients with IBD and 38 healthy subjects (HS) Section |
cohort.total_participants |
273 computed |
235 patients with IBD and 38 healthy subjects (HS) Section |
cohort.treatment_exposure_documented |
True |
adjusted all analyses for age, gender, smoking and treatment Section |
Specimens
| Field | Value | Evidence |
|---|---|---|
specimens.body_site |
faecal |
Faecal samples were collected from 235 patients with IBD and 38 HS. Section |
specimens.number_of_samples |
273 computed |
Faecal samples were collected from 235 patients with IBD and 38 HS. Section |
specimens.sample_type |
stool |
Faecal samples were collected from 235 patients with IBD and 38 HS. Section |